Gerresheimer AG : Q4 due 17 Feb – Top line top, adj. EBITDA margin burdened by input costs
>A solid finish to FY 2020-21 estimated - Again driven partially by inflationary tailwinds, we estimate sales growth of 8.9% y/y for Q4 (5.9% y/y ex FX, inflationary tailwinds; +7.4% y/y for the core) with our sales forecast standing at € 438.8m. Mainly driven by headwinds from higher input costs also in Q4 (energy costs), we forecast the adj. EBITDA margin to have declined from 24.8% in Q4 2019-20 to 22.9% in Q4 2020/21 with our adj. EBITDA forecast standing at € 10...Gerresheimer is a holding company. Through its subsidiaries, Co. manufactures glass and plastic products for the pharma and healthcare industry. Co.'s operates in three divisions: Plastics & Devices, which its product portfolio includes products for the administration of medicines, such as insulin pens, inhalers, and prefillable syringes; Primary Packaging Glass, which produces glass primary packaging for medicines and cosmetics, such as pharma jars, ampoules, injection vials, cartridges, perfume flacons, and cream jars; and Life Science Research, which produces laboratory glassware for research, development, and analytics, such as beakers, Erlenmeyer flasks, and measuring cylinders.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.